Device Trial Radar · NCT07457216
Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation
Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 3, 2025
Primary completion
Jan 30, 2025
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- Benha UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates visual outcomes and patient-reported satisfaction following bilateral cataract surgery using a non-diffractive extended depth-of-focus (EDOF) intraocular lens (AcrySof IQ Vivity). The purpose of the study is to assess distance, intermediate, and near visual acuity, refractive accuracy, contrast sensitivity, spectacle independence, and the presence of photic phenomena after implantation. Thirty patients undergoing bilateral phacoemulsification will be enrolled. Participants will be evaluated at 1 and 3 months postoperatively.
Conditions
- Extended Depth-of-Focus Intraocular Lens
- Cataract
- Visual Acuity
Interventions
AcrySof IQ Vivity EDOF Intraocular LensDevice
The AcrySof IQ Vivity is a non-diffractive extended depth-of-focus intraocular lens designed to provide an extended range of clear vision for distance and intermediate tasks while maintaining high optical quality and reducing photic phenomena such as glare and halos. The lens is implanted in the capsular bag during standard phacoemulsification surgery. Target refraction is emmetropia, and postoperative care includes a 4-week taper of combined topical antibiotic-steroid drops. Outcomes measured include visual acuity at distance, intermediate, and near, patient satisfaction, spectacle independence, and contrast sensitivity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Binocular Uncorrected Distance Visual Acuity (UDVA)Time frame: 1 month and 3 months postoperatively
- Monocular Uncorrected Distance Visual Acuity (UDVA)Time frame: 1 month and 3 months postoperatively
- Binocular Uncorrected Intermediate Visual Acuity (UIVA at 66 cm)Time frame: 1 month and 3 months postoperatively
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Benha University
Banhā, Benha, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.